ARGX

701

-0.82%↓

SHL.DE

34.58

+0.26%↑

FRE

38.84

-2.92%↓

PHIA

23.42

+0.95%↑

FME

37.3

-4.04%↓

ARGX

701

-0.82%↓

SHL.DE

34.58

+0.26%↑

FRE

38.84

-2.92%↓

PHIA

23.42

+0.95%↑

FME

37.3

-4.04%↓

ARGX

701

-0.82%↓

SHL.DE

34.58

+0.26%↑

FRE

38.84

-2.92%↓

PHIA

23.42

+0.95%↑

FME

37.3

-4.04%↓

ARGX

701

-0.82%↓

SHL.DE

34.58

+0.26%↑

FRE

38.84

-2.92%↓

PHIA

23.42

+0.95%↑

FME

37.3

-4.04%↓

ARGX

701

-0.82%↓

SHL.DE

34.58

+0.26%↑

FRE

38.84

-2.92%↓

PHIA

23.42

+0.95%↑

FME

37.3

-4.04%↓

Home・Aandelen Lijst・Sanofi SA

Search

Sanofi SA

Gesloten

SectorGezondheidszorg

76.89 -0.91

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

76.87

Max

78.02

Belangrijke statistieken
By Trading Economics
Inkomsten	-394M 1.6B
Verkoop	-12B 11B
K/W Sectorgemiddelde	18.773 49.701
EPS	1.88
Winstmarge	14.354
Werknemers	74,846
EBITDA	1.5B 2.7B

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+24.2% upside

Dividenden
By Dow Jones
Volgende Winsten	30 jul 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-9.6B 89B
Vorige openingsprijs	77.8
Vorige sluitingsprijs	76.89

Nieuwssentiment

By Acuity

37%

63%

95 / 345 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

91.3 / 96.1 Steun & Weerstand

Sanofi SA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 apr 2026, 09:03 UTC

Winsten

Spain's Santander Profit Climbs Amid Global Portfolio Reshuffle -- Update

29 apr 2026, 05:27 UTC

Winsten

Santander Books Jump in Profit on Top-Line Growth, Lower Costs

23 apr 2026, 06:12 UTC

Winsten

Sanofi Posts Higher Sales Amid Leadership Transition

7 mei 2026, 06:47 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Sanofi Needs Acquisitions to Overcome Pipeline Disappointments -- Market Talk

1 mei 2026, 06:14 UTC

Acquisities, Fusies, Overnames

Santander UK to Also Pay GBP213M Based on TSB's Tangible NAV

1 mei 2026, 06:13 UTC

Acquisities, Fusies, Overnames

Santander UK Also Financed Deal From Funding by Parent, Banco Santander

1 mei 2026, 06:12 UTC

Acquisities, Fusies, Overnames

Santander UK Financed Deal From Existing Cash Resources

1 mei 2026, 06:08 UTC

Acquisities, Fusies, Overnames

Santander UK Announced Key Terms of Deal July 2025

1 mei 2026, 06:03 UTC

Acquisities, Fusies, Overnames

Santander UK Buys TSB Banking for GBP2.65B

1 mei 2026, 06:02 UTC

Acquisities, Fusies, Overnames

Santander UK Buys TSB Banking Group

29 apr 2026, 12:01 UTC

Winsten

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

29 apr 2026, 06:27 UTC

Marktinformatie

Winsten

Santander's Above-Forecast Earnings Should Be Well-Received -- Market Talk

29 apr 2026, 04:55 UTC

Winsten

Analysts Saw Santander 1Q Loan Loss Provisions EUR3.12B

29 apr 2026, 04:55 UTC

Winsten

Santander 1Q Loan Loss Provisions EUR3.225B

29 apr 2026, 04:54 UTC

Winsten

Analysts Saw Santander 1Q Operating Expenses EUR6.57B

29 apr 2026, 04:54 UTC

Winsten

Santander 1Q Operating Expenses EUR6.48B

29 apr 2026, 04:52 UTC

Winsten

Santander Backs 2028 View

29 apr 2026, 04:52 UTC

Winsten

Santander Backs 2026 View

29 apr 2026, 04:52 UTC

Winsten

Santander 1Q Underlying RoTE 15.2%

29 apr 2026, 04:51 UTC

Winsten

Santander End-1Q CET1 Ratio 14.4%

29 apr 2026, 04:51 UTC

Winsten

Analysts Saw Santander 1Q Net Interest Income EUR10.86B

29 apr 2026, 04:51 UTC

Winsten

Santander 1Q Net Interest Income EUR11.02B

29 apr 2026, 04:50 UTC

Winsten

Analysts Saw Santander 1Q Underlying Net Pft EUR3.47B

29 apr 2026, 04:50 UTC

Winsten

Santander 1Q Underlying Pft EUR3.56B

29 apr 2026, 04:49 UTC

Winsten

Santander 1Q Net Pft EUR5.455B

29 apr 2026, 04:49 UTC

Winsten

Analysts Saw Santander 1Q Rev EUR15.00B

29 apr 2026, 04:49 UTC

Winsten

Santander 1Q Rev EUR15.14B

27 apr 2026, 09:32 UTC

Marktinformatie

Winsten

Sanofi's Dupixent Sales Growth Set to Moderate -- Market Talk

27 apr 2026, 09:19 UTC

Marktinformatie

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

23 apr 2026, 05:34 UTC

Winsten

Sanofi: 2026 Expectations Are at Constant Exchange Rates

Peer Vergelijking

Prijswijziging

Sanofi SA Prognose

Koersdoel

By TipRanks

24.2% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 95.221 EUR 24.2%

Hoogste 107 EUR

Laagste 85 EUR

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Sanofi SA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

9 ratings

4

Buy

5

Hold

0

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Sanofi SA - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

91.3 / 96.1Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

95 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Andere aandelen uit de sector

ARGX

Argenx SE

701

SHL.DE

Siemens Healthineers AG

34.58

FRE

Fresenius SE & Co KGaA

38.84

PHIA

Koninklijke Philips NV

23.42

FME

Fresenius Medical Care AG

37.3

Live chat